Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis-Reference-Cited by-同舟云学术

Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis

Published:2006-10-05 Issue:1 Volume:21 Page:143-150
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Gutiérrez N C, ,Castellanos M V,Martín M L,Mateos M V,Hernández J M,Fernández M,Carrera D,Rosiñol L,Ribera J M,Ojanguren J M,Palomera L,Gardella S,Escoda L,Hernández-Boluda J C,Bello J L,de la Rubia J,Lahuerta J J,San Miguel J F

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/2404413.pdf

Reference29 articles.

1. San Miguel JF, García-Sanz R . Prognostic features of multiple myeloma. Best Pract Res Clin Haematol 2005; 18: 569–583.

2. Tricot G, Barlogie B, Jagannath S, Bracy D, Mattox S, Vesole DH et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 1995; 86: 4250–4256.

3. Moreau P, Facon T, Leleu X, Morineau N, Huyghe P, Harousseau JL et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 2002; 100: 1579–1583.

4. Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003; 101: 4569–4575.

5. Shaughnessy Jr J, Tian E, Sawyer J, McCoy J, Tricot G, Jacobson J et al. Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II. Br J Haematol 2003; 120: 44–52.

Cited by 159 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Precision medicine for multiple myeloma: The case for translocation (11;14);Cancer Treatment Reviews;2024-11

2. Clinical practice guidelines for molecular tumor marker, 2nd edition review part 2;International Journal of Clinical Oncology;2024-03-17

3. Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma;Blood;2023-11-02

4. Reduction rate of monoclonal protein as a useful prognostic factor in standard-risk group of newly diagnosed multiple myeloma;World Journal of Clinical Cases;2023-08-26

5. Multiple myeloma with t(11;14): impact of novel agents on outcome;Blood Cancer Journal;2023-03-20